Poolbeg Pharma

1. 06 Oct 26
   POLB001 CRS Patent Granted in South Korea

   Cancer Immunotherapy-Induced CRS Patent Granted in South Korea

   RNS 9807690 ↗
2. 29 Sep 26
   Half-year Results

   Interim Results for the six months to 30 June 2026

   RNS 9795180 ↗
3. 28 Sep 26
   POLB 001 TOPICAL trial recruitment update

   28 September 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, reaffirms that participant recruitment for the POLB 001 TOPICAL trial...

   RNS 9792832 ↗
4. 24 Sep 26
   Interim data from POLB 001 TOPICAL clinical trial

   Interim data from POLB 001 TOPICAL clinical trial

   RNS 9787989 ↗
5. 03 Sep 26
   Key Conference Participation in September 2026

   Poolbeg Pharma to Participate in Key Conferences in September 2026

   RNS 9752917 ↗
6. 21 Jul 26
   Notice of Allowance for POLB 001 patent in Israel

   Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel

   RNS 9678499 ↗
7. 14 Jul 26
   Placing to raise £3.5 million

   CERTAIN OF THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU 596/2014) AS THE SAME CURRENTLY FORMS PART OF ENGLISH LAW.

   RNS 9666653 ↗
8. 13 Jul 26
   First patient dosed in POLB 001 TOPICAL trial

   First Patient Dosed in the POLB 001 TOPICAL Clinical Trial

   RNS 9664236 ↗
9. 30 Jun 26
   POLB 001 patent granted in South Africa

   POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza

   RNS 9643061 ↗
10. 16 Jun 26
    European patent granted for POLB 001 in CRS

    Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS

    RNS 9619776 ↗
11. 11 Jun 26
    Preclinical data posters presented at EHA Congress

    Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

    RNS 9612700 ↗
12. 11 Jun 26
    POLB 001 TOPICAL Site Activation

    Poolbeg Pharma Announces Successful Site Activation for POLB 001 TOPICAL Clinical Trial

    RNS 9612474 ↗
13. 09 Jun 26
    Results of AGM & Change of Registered Address

    Results of AGM & Change of Registered Address

    RNS 9609641 ↗
14. 26 May 26
    Pre-IND Meeting with the FDA for POLB 001

    Pre-IND Meeting with the FDA for POLB 001

    RNS 9583992 ↗
15. 13 May 26
    POLB 001 poster to be presented at EHA 2026

    POLB 001 poster to be presented at EHA 2026 Congress

    RNS 9565155 ↗
16. 11 May 26
    POLB 001 CRS patent granted in Canada

    POLB 001 cancer immunotherapy-induced CRS patent granted in Canada

    RNS 9560471 ↗
17. 07 May 26
    Annual Report & AGM Notice

    7 May 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, confirms that the Company's Annual Report and Accounts for the period ended 31...

    RNS 9555991 ↗
18. 28 Apr 26
    Results for the year ended 31 December 2025

    Results for the year ended 31 December 2025

    RNS 9540468 ↗
19. 15 Apr 26
    MHRA grants CTA for the POLB 001 TOPICAL trial

    MHRA grants Clinical Trial Authorisation for the TOPICAL trial and independent research confirms significant commercial opportunity for POLB 001

    RNS 9520468 ↗
20. 31 Mar 26
    Significant milestone for Poolbeg's IP portfolio

    Grant of first POLB 001 cancer immunotherapy-induced CRS patent

    RNS 9499253 ↗
21. 12 Mar 26
    Appointment of Dr Adrian Kilcoyne to SAB

    Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board

    RNS 9470379 ↗
22. 28 Jan 26
    POLB 001 LPS Challenge Trial Paper Published

    Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology

    RNS 9390359 ↗
23. 18 Dec 25
    Letter to Shareholders – 2025 a year of progress

    Letter to Shareholders - 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected

    RNS 9305036 ↗
24. 08 Dec 25
    POLB 001 to feature in CRS research programme

    POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

    RNS 9281212 ↗
25. 20 Nov 25
    POLB 001 European Patent granted

    20 November 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg's European...

    RNS 9245480 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.